EuroPCR 2025 | EMPOWER CAD

Women are underrepresented in numerous percutaneous transluminal coronary angioplasty (PTCA) studies, particularly in those analyzing calcified or high-risk lesions. This leads to worse clinical outcomes for this group.

Researchers conducted an analysis on 389 women with severely calcified coronary lesions who were treated with coronary lithotripsy.

The average age was 73 years; 46% of subjects had diabetes, 32% had a history of myocardial infarction, 38% had undergone prior PTCA, and 28% had impaired renal function.

Additionally, 46% had stable coronary syndrome, 24% had non-ST-elevation myocardial infarction (NSTEMI), while unstable angina and ST-elevation myocardial infarction (STEMI) were less frequent.

At 30 days, cardiac mortality was 1.3%, the infarction rate was 10.6%, and the target lesion revascularization (TLR) rate was 1.3%. There was a significant improvement in quality of life.

Presented by Margaret McEntergart during EuroPCR 2025 in Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....